Safety and Efficacy of Inhaled Treprostinil in Subjects with PH due to Parenchymal Lung Disease 2017-08-30T18:36:10+00:00

Clinical Trials

Aug. 30 2017

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease

  • Study Sponsor: United Therapeutics Corporation
  • Institution: United Therapeutics Corp.
  • Start Date: Tuesday, May 24, 2016
  • End Date: Monday, December 31, 2018
  • Design: Multicenter, randomized, double-blinded, placebo-controlled
  • Age range (years): 18 Years and older
  • Type of PH
    • PH with interstitial lung disease (ILD), including combined pulmonary fibrosis and emphysema (CPFE)
  • Study Duration for individual patient: 16 Weeks with a 2 year Open-Label Extension Study
  • Contact: Kristan Rollins – krollins@unither.com
  • Listing on clinicaltrials.gov